[go: up one dir, main page]

WO2002016358A3 - Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) - Google Patents

Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) Download PDF

Info

Publication number
WO2002016358A3
WO2002016358A3 PCT/US2001/021138 US0121138W WO0216358A3 WO 2002016358 A3 WO2002016358 A3 WO 2002016358A3 US 0121138 W US0121138 W US 0121138W WO 0216358 A3 WO0216358 A3 WO 0216358A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinuclidine
disease
treatment
substituted aryl
acetylcholine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021138
Other languages
French (fr)
Other versions
WO2002016358A2 (en
Inventor
Jason K Myers
Vincent E Groppi Jr
David W Piotrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Priority to EP01961625A priority Critical patent/EP1381603A2/en
Priority to AU2001282874A priority patent/AU2001282874A1/en
Priority to JP2002521459A priority patent/JP2004506735A/en
Publication of WO2002016358A2 publication Critical patent/WO2002016358A2/en
Publication of WO2002016358A3 publication Critical patent/WO2002016358A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides compounds of Formula (I). These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in which α7 is known to be involved.
PCT/US2001/021138 2000-08-18 2001-08-17 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands) Ceased WO2002016358A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01961625A EP1381603A2 (en) 2000-08-18 2001-08-17 Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
AU2001282874A AU2001282874A1 (en) 2000-08-18 2001-08-17 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
JP2002521459A JP2004506735A (en) 2000-08-18 2001-08-17 Quinuclidine-substituted aryl compounds for disease treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22616400P 2000-08-18 2000-08-18
US60/226,164 2000-08-18
US28496601P 2001-04-19 2001-04-19
US60/284,966 2001-04-19

Publications (2)

Publication Number Publication Date
WO2002016358A2 WO2002016358A2 (en) 2002-02-28
WO2002016358A3 true WO2002016358A3 (en) 2002-07-18

Family

ID=26920268

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021138 Ceased WO2002016358A2 (en) 2000-08-18 2001-08-17 Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)

Country Status (6)

Country Link
US (1) US6479510B2 (en)
EP (1) EP1381603A2 (en)
JP (1) JP2004506735A (en)
AU (1) AU2001282874A1 (en)
PE (1) PE20030226A1 (en)
WO (1) WO2002016358A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9434724B2 (en) 2014-07-11 2016-09-06 Alpharmagen, Llc Quinuclidines for modulating alpha 7 activity

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
GB0010955D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds
WO2003018585A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
PL369895A1 (en) 2001-10-02 2005-05-02 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
WO2003032897A2 (en) * 2001-10-16 2003-04-24 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
NZ533259A (en) 2001-12-14 2007-10-26 Targacept Inc Methods and compositions for treatment of central nervous system disorders
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US7238715B2 (en) * 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
ATE378048T1 (en) * 2002-12-06 2007-11-15 The Feinstein Inst Medical Res INHIBITION OF INFLAMMATION USING ALPHA-7 RECEPTOR-LINKING CHOLINERGIC AGONISTS
WO2004052889A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
WO2005037832A2 (en) 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
EP1687004A4 (en) * 2003-11-10 2009-04-08 Synta Pharmaceuticals Corp Pyridine compounds
US20050137398A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
PE20060437A1 (en) 2004-06-18 2006-06-08 Novartis Ag AZA-BICYCLONONE COMPOUNDS AS CHOLINERGIC LINKS OF nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006014012A2 (en) 2004-08-06 2006-02-09 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
JP2009506037A (en) 2005-08-22 2009-02-12 ターガセプト，インコーポレイテッド Heteroaryl-substituted diazatricycloalkanes, methods for their preparation and methods for their use
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
EP1957073B1 (en) 2005-12-05 2014-04-23 Otsuka Pharmaceutical Co., Ltd. Medicinal drug
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
AU2006329007A1 (en) * 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
UA95978C2 (en) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Stat3/5 activation inhibitor
SA08290475B1 (en) 2007-08-02 2013-06-22 Targacept Inc (2S,3R)-N-(2-((3-pyrdinyl)methyl)-1-aza bicyclo[2,2,2]oct-3-yl)benzofuran-2-carboxamide, its new salt forms and methods of use
CN104193741B (en) 2007-10-01 2016-08-24 阿尔法梅根有限责任公司 Quinuclidine-4-ylmethyl 1H-indole-3-carboxylic acid ester derivant as alpha 7 nicotinic acetylcholine receptor ligands
WO2009102962A2 (en) 2008-02-13 2009-08-20 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
KR20140146216A (en) 2008-11-19 2014-12-24 포럼 파마슈티칼즈 인크. Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
MX2011011972A (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals Inc Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors.
JO3078B1 (en) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv Morpholinothiazoles as alpha 7 positive allosteric modulators
PL3029039T3 (en) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
HK1208356A1 (en) 2012-05-08 2016-03-04 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327335A1 (en) * 1988-02-01 1989-08-09 Synthelabo Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency
EP0353371A1 (en) * 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
WO1992011259A1 (en) * 1990-12-19 1992-07-09 Beecham Group Plc Azabicyclic amides or esters of halogenated benzoic acids
US5237066A (en) * 1987-02-04 1993-08-17 Delande S.A. Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy
WO1996040100A1 (en) * 1995-06-07 1996-12-19 3-Dimensional Pharmaceuticals, Inc. ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS
WO1997030998A1 (en) * 1996-02-23 1997-08-28 Astra Aktiebolag Azabicyclic esters of carbamic acids useful in therapy
WO2001029034A1 (en) * 1999-10-18 2001-04-26 Astrazeneca Ab Quinuclidine acrylamides
WO2001036417A1 (en) * 1999-11-18 2001-05-25 Astrazeneca Ab New use and novel n-azabicyclo-amide derivatives
WO2001060821A1 (en) * 2000-02-18 2001-08-23 Astrazeneca Ab Novel biarylcarboxamides

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702324A (en) 1970-06-24 1972-11-07 Stanford Research Inst 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines
US4093734A (en) 1975-11-03 1978-06-06 Boehringer Ingelheim Gmbh Amino-benzoic acid amides
FR2531083B1 (en) 1982-06-29 1986-11-28 Sandoz Sa NOVEL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES
FR2529548A1 (en) 1982-07-02 1984-01-06 Delalande Sa NOVEL DERIVATIVES OF AMINO-3 QUINUCLIDINE, THEIR PROCESS AND THEIR THERAPEUTIC APPLICATION
US5175173A (en) 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US4593034A (en) 1984-04-06 1986-06-03 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
US4820715A (en) 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
US4870181A (en) 1985-02-04 1989-09-26 A. H. Robins Company, Incorporated Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2])octan-3-yl)aminobenzamides
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3689974T2 (en) 1985-03-14 1994-11-03 Beecham Group Plc Medicines to treat emesis.
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
US4717563A (en) 1986-03-05 1988-01-05 A. H. Robins Company, Inc. 2-alkoxy-N-(1-azabicyclo(2.2.2)oct-3-yl) benzamides and thiobenzamides in a method for alleviating emesis caused by non-platinum anticancer drugs
NL8701682A (en) 1986-07-30 1988-02-16 Sandoz Ag METHOD FOR THE THERAPEUTIC USE OF SEROTONIN ANTAGONISTS, ACTIVE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS
ES2051753T3 (en) 1986-12-16 1994-07-01 Robins Co Inc A H N- (1-AZABICICLO (2.2.2) OCTO-3-IL) BENZAMIDES AND ANSIOLYTIC THIOBENZAMIDES.
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
DE3822792C2 (en) 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
GB8718345D0 (en) 1987-08-03 1987-09-09 Fordonal Sa N-substituted benzamides
GB8720805D0 (en) 1987-09-04 1987-10-14 Naylor R J 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
US4921982A (en) 1988-07-21 1990-05-01 Eli Lilly And Company 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists
US5206246A (en) 1987-10-16 1993-04-27 A. H. Robins Company, Incorporated Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides
IE63474B1 (en) 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
FR2625678B1 (en) 1988-01-13 1991-06-07 Delalande Sa ANOREXIGENAL AGENTS BASED ON N- (QUINUCLIDIN-3-YL) -BENZAMIDES OR THIOBENZAMIDES
DE3810552A1 (en) 1988-03-29 1989-10-19 Sandoz Ag Esters and amides of indole-, benzo[b]thiophene or benzo[b]furancarboxylic acids or 4-amino-2-methoxybenzoic acids with N-heterocyclic or N-heterobicyclic alcohols or amines, processes for their preparation, pharmaceutical compositions containing them and applicator for administration thereof
US5246942A (en) 1988-04-27 1993-09-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration
DE3878235T2 (en) 1988-08-04 1993-06-03 Synthelabo ANTISCHIZOPHREN EFFECTIVE S-N- (1-AZABICYCLO (2.2.2.) OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES.
WO1990014347A1 (en) 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Indole derivatives and medicine
US5290938A (en) 1989-09-15 1994-03-01 Chiron Laboratories A.S. Preparation of S-(-)- and R-(+)-N-(quinuclidinyl-3)-amide
EP0436245A1 (en) 1989-12-27 1991-07-10 Duphar International Research B.V Substituted 3,4-annelated benzimidazol-2(1H)-ones
US5057519A (en) 1990-06-11 1991-10-15 Bristol-Myers Squibb Company 5-HT3 antagonists: use in reducing opiate tolerance
US5070095A (en) 1990-12-12 1991-12-03 A. H. Robins Company, Incorporated Substituted 4-(amidino)benzamides of 1-azabicyclo[2.2.2]octan-3- and -4-amine as gastric prokinetic, antiemetic, and anxiolytic agents
US5084460A (en) 1990-12-24 1992-01-28 A. H. Robins Company, Incorporated Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
JPH06506467A (en) 1991-03-08 1994-07-21 ローヌ−プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド Polycyclic tertiary amine polyaromatic squalene synthetase inhibitor
US5491148A (en) 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
DE4115215A1 (en) 1991-05-10 1992-11-12 Merck Patent Gmbh INDOLDER DERIVATIVES
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5236931A (en) 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
WO1994020617A2 (en) 1993-03-08 1994-09-15 The Salk Institute Biotechnology/Industrial Associates, Incorporated Human neuronal nicotinic acetylcholine receptor compositions and methods employing same
IL109451A0 (en) 1993-04-29 1994-07-31 Zeneca Ltd Heterocyclic derivatives
US5723103A (en) 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
EP1180142A2 (en) 1999-05-27 2002-02-20 PHARMACIA & UPJOHN COMPANY Methods and compositions for measuring ion channel conductance

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237066A (en) * 1987-02-04 1993-08-17 Delande S.A. Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy
EP0327335A1 (en) * 1988-02-01 1989-08-09 Synthelabo Arylamido(and arylthioamido)-azabicycloalkanes for enhancing memory or correcting memory deficiency
EP0353371A1 (en) * 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
WO1992011259A1 (en) * 1990-12-19 1992-07-09 Beecham Group Plc Azabicyclic amides or esters of halogenated benzoic acids
WO1996040100A1 (en) * 1995-06-07 1996-12-19 3-Dimensional Pharmaceuticals, Inc. ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS
WO1997030998A1 (en) * 1996-02-23 1997-08-28 Astra Aktiebolag Azabicyclic esters of carbamic acids useful in therapy
WO2001029034A1 (en) * 1999-10-18 2001-04-26 Astrazeneca Ab Quinuclidine acrylamides
WO2001036417A1 (en) * 1999-11-18 2001-05-25 Astrazeneca Ab New use and novel n-azabicyclo-amide derivatives
WO2001060821A1 (en) * 2000-02-18 2001-08-23 Astrazeneca Ab Novel biarylcarboxamides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BANNON A W ET AL: "BROAD-SPECTRUM, NON-OPIOID ANALGESIC ACTIVITY BY SELECTIVE MODULATION OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 279, no. 5347, 1998, pages 77 - 81, XP000906771, ISSN: 0036-8075 *
DINELEY K T ET AL: "Amino acid determinants of alpha-7 nicotinic acetylcholine receptor surface expression", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 18, 5 May 2000 (2000-05-05), pages 13974 - 13985, XP002157175, ISSN: 0021-9258 *
HOLLADAY ET AL: "Neuronal Nicotinic Acetylcholine Receptros as Targets for Drug Discovery", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 26, 19 December 1997 (1997-12-19), pages 4169 - 4194, XP002124847, ISSN: 0022-2623 *
J-L EISELE ET AL: "CHIMAERIC NICOTINIC-SEROTONERGIC RECEPTOR COMBINES DISTINCT LIGAND BINDING AND CHANNEL SPECIFICITIES", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 366, 2 December 1993 (1993-12-02), pages 479 - 483, XP002157172, ISSN: 0028-0836 *
KUNTZWEILER T A ET AL: "RAPID ASSESSMENT OF LIGAND ACTIONS WITH NICOTINIC ACETYLCHOLINE RECEPTORS USING CALCIUM DYNAMICS AND FLIPR", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 44, no. 1, May 1998 (1998-05-01), pages 14 - 20, XP000971806, ISSN: 0272-4391 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9434724B2 (en) 2014-07-11 2016-09-06 Alpharmagen, Llc Quinuclidines for modulating alpha 7 activity

Also Published As

Publication number Publication date
PE20030226A1 (en) 2003-03-14
AU2001282874A1 (en) 2002-03-04
JP2004506735A (en) 2004-03-04
US20020049225A1 (en) 2002-04-25
EP1381603A2 (en) 2004-01-21
US6479510B2 (en) 2002-11-12
WO2002016358A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
WO2002016357A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016358A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016356A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002017358A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
WO2002016355A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
MXPA04004464A (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease.
WO2003093250A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2002100858A3 (en) Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
MXPA03011484A (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.
WO2003070731A3 (en) Azabicyclic compounds for the treatment of disease
WO2004085433A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
ATE361287T1 (en) NEW INDOL-2-ON DERIVATIVES
MXPA04001500A (en) Compounds effecting glucokinase.
NO20052802L (en) Pyrrolopyrimidinderivativer
WO2005018557A3 (en) Substituted pyridinones
WO2006011050A3 (en) Pyridine derivatives
CA2410234A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
WO2003006670A3 (en) 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
PT992509E (en) NEW MACROLIDED DERIVATIVES
WO2005000815A3 (en) Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor
HK1053833A1 (en) Substituted phenyl farnesyltransferase inhibitors
WO2003070728A3 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002521459

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001961625

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001961625

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001961625

Country of ref document: EP